Cytonics Corporation

🌐 Exclusive Investor Webinar TODAY @ 4pm ET Don’t miss your chance to chat with Joey Bose, our President & CEO about everything biotech! Seize this opportunity to connect directly with our CEO and learn all about the biotech industry and Cytonics’ mission to rid the world of osteoarthritis. Register now! 🌐 https://lnkd.in/eCJ8XmRM #biotechnology #CEO #webinar #arthritis #investing #crowdfunding #drugdevelopment

🌟 Professional Brazilian Jiu Jitsu And WWE Athletes Join Cytonics as Strategic Investors We're thrilled to announce that Rener Gracie and Eve Gracie have made a 💸 substantial investment in Cytonics, joining us as both shareholders and strategic partners. 🥋 The Gracies, renowned figures in the Brazilian Jiu Jitsu, MMA, and pro wrestling communities, bring not only their 💰 financial support but also their extensive network and influence in the athletic community. The involvement of the Gracies will play a significant role in Cytonics’ fundraising efforts as we advance our groundbreaking therapy, 💊 CYT-108, into Phase 2 clinical trials. Their advocacy and connections within the Brazilian Jiu Jitsu, MMA, and pro wrestling communities will not only raise awareness of our cutting-edge treatments for osteoarthritis, but also facilitate future capital raising efforts, ensuring that we have the resources necessary to advance CYT-108 through FDA clinical trials 🧬. 🤝 This partnership involves much more than just an investment. It is a strategic alliance that leverages the Gracies' influence and reach to allow our mission to resound with the people that need treatment for arthritis the most: 🦿 from professional athletes to the casual jogger. ❤️ Together, we are poised to make a significant impact on the lives of millions suffering from joint damage and osteoarthritis. Are you ready to join the Gracies and become a shareholder in Cytonics? 🪙 Visit invest.cytonics.com to learn more about the investment opportunity. #jiujitsu #gracieuniversity #biotechnology #cytonics #drugdevelopment #investing #MMA #arthritis

❗INTERIM PHASE 1 UPDATE❗ 📍 13 patients dosed, beating enrollment expectations We are thrilled to share an exciting update from our ongoing Phase 1 clinical trial for CYT-108. As of now, 13 patients have been successfully 💉 dosed out of the 20 total participants, surpassing our initial enrollment expectations. Even more encouraging is the fact that no adverse events have been reported so far. We anticipate having the full Phase 1 clinical report 📖 available in Q3/Q4 2025. This progress brings us one step closer to our goal of providing a groundbreaking treatment for osteoarthritis. We extend our deepest gratitude 🤝 our shareholders for your unwavering support and belief in our mission. Your investment has been instrumental in reaching this pivotal milestone, and we are committed to maximizing shareholder value by efficient capital allocation. Approximately 70% of all investor dollars 💵 are spent directly on research and development of CYT-108.   ❤️ Thank you once again for your continued support. Together, we can usher in a future where osteoarthritis is a thing of the past. invest.cytonics.com #biotechnology #arthritis #clinicaltrials #drugdevelopment #investing

🗝️ Keys To Biotech Startup Success 📐 Measure Twice ✂️ Cut Once Plotting the trajectory of a company from seed-stage to an “exit” is the single-most important task that management teams frequently deprioritize (and understandably so… building technologies is way more interesting than drawing up timelines and gantt charts!). Regardless of the nature of the startup business, the universal end goal is to maximize shareholder value and provide early investors with the opportunity to cash out. A simple concept that becomes infinitely more complex when put into practice. Luckily, pharmaceutical discovery and development follows a linear path through the FDA’s regulatory framework, making it relatively simple to chart the growth of the company and the milestones that “move the valuation needle.” But the Devil is in the details, and a comprehensive drug development, clinical trial management, and M&A / IPO strategy is absolutely crucial to maximizing shareholder value. 🪙 Maximizing Shareholder Value As we approach a significant milestone with the completion of our Phase 1 study in June 2025, we are poised for transformative growth. Success in Phase 1 will pave the way for Phase 2 and 3 trials, and open doors to strategic partnership opportunities, M&A, and public listings. Here are the activities that lie on our path of shareholder value creation: ✅ First-In-Human: After 6 years and $10M spent in drug discovery and preclinical development, our novel therapy for osteoarthritis, CYT-108, is finally ready for primetime… a first-in-human Phase 1 clinical trial to assess the safety and efficacy of the drug in patients suffering from mild-to-moderate osteoarthritis. ✅ Strategic Collaborations: Successful Phase 1 trials could attract interest from major industry players. With Johnson & Johnson holding a 12% stake in Cytonics, they are well-positioned as a primary potential acquirer or collaborator for Phase 2 clinical studies. ✅ Future Funding: Positive results from our Phase 1 clinical trials may enable us to pursue a substantial $20M funding round for Phase 2, and serve as a strong predicate for a $100M raise to support the pivotal Phase 2/3 clinical trial. ✅ Phase 2/3: Positive Phase 2 and 3 datasets may offer definitive proof that CYT-108 can restore quality of life and mobility for osteoarthritis patients. Large pharmaceutical companies love to partner or acquire drug assets that have been “de-risked” with Phase 2 data… their risk-reward sweet spot. ✅ New Drug Approval: FDA approval would position CYT-108 as the first and only disease-modifying treatment for osteoarthritis. At this stage, Cytonics would consider an Initial Public Offering (IPO) to provide liquidity for our shareholders and possibly raise funds for future drug development programs. #biotechnology #drugdevelopment #investing #arthritis

❗BREAKING❗1st Patient Dosed in Ph 1 Clinical Trial Last night 💉 we dosed our first patient in our Phase 1 clinical trial of CYT-108 for the treatment of osteoarthritis. The patient received 25mg of CYT-108, our recombinant Alpha-2-Macroglobulin variant. They were observed for 30 minutes and no acute adverse events were detected. This event marks our transition from a preclinical research company to a clinical-stage company, a massive milestone that underscores our commitment to transforming the treatment of osteoarthritis. 📅 Timeline and Next Steps This patient will receive their final dose in late September, with the last follow-up scheduled for January 2025. Over the next two months, we anticipate enrolling and dosing approximately 20 more patients, keeping us on track for the Phase 1 clinical report to be published in June 2025. Each step brings us closer to our goal of providing a disease-modifying treatment for osteoarthritis, potentially benefiting millions of patients worldwide. Many more updates to come! #arthritis #regenerativemedicine #clinicaltrials #Cytonics #biotechnology

❗Patient Recruitment for Phase 1 Trial is Underway We’ve screened over 20 patients and are set to begin dosing soon! This is a monumental step forward in Cytonics Corporation's mission to develop the first and only disease-modifying treatment for osteoarthritis. ✨ Upcoming Milestones ➡️ First patient will receive their first dose within weeks! ➡️ Recruiting will complete before August 2024 ➡️ Last patient will receive their last dose before December 2024 ➡️ The Phase 1 clinical report will ready by June 2025 Sign up to receive clinical trial updates and participate in future investment opportunities by visiting www.cytonics.com #ClinicalTrials #MedicalResearch #Arthritis #JointHealth #CartilageRepair #Biopharma

Phase 1 Update 🚀 Exciting Milestone Achieved! 🌟 We are thrilled to announce that Cytonics Corporation's clinical sites are now activated for our Phase 1 study of CYT-108 as a treatment for #osteoarthritis! 🏥 What is Clinical Site Activation? Clinical site activation is a comprehensive process that ensures each site is fully prepared to begin patient recruitment and conduct the clinical trial. This includes obtaining regulatory approvals, training staff, and setting up necessary equipment and systems. 🔬 ✅ Why is This Important? Activating our clinical sites is a pivotal step, ensuring we are ready to conduct our study with the highest standards of accuracy and integrity. This readiness is essential for generating reliable and robust clinical data. 📊 💉 What Does This Mean for Our Study? With our sites now activated, we are ready to begin patient recruitment and start the clinical trial. This significant advancement brings us closer to offering a transformative treatment for osteoarthritis. 🌐 🙏 Stay tuned for more updates as we embark on this exciting phase! #ClinicalResearch #Biotech #HealthcareInnovation #ClinicalTrials #CYT108 #RegenerativeMedicine #Biopharmaceuticals #MedicalResearch #Cytonics

🥇 Another Successful Crowdfund In The Books! 🌟 Over 1,600 new investors contributed $3.7M to catapult Cytonics Corporation into clinical trials! This tremendous achievement means we are now fully funded through our next major milestone: the Phase 1 clinical trials for CYT-108 as a treatment for osteoarthritis (OA). This funding positions us to have human clinical data by June 2025, a critical step in our journey to bring lasting relief to the millions suffering from osteoarthritis. We anticipate recruiting our first patient in the Phase 1 trial within the next few weeks, marking our transition from a preclinical research company to a clinical development-stage biopharmaceutical company. The first patient will receive their first dose before July 2024, and the last patient will receive their last dose by January 2025. This is a HUGE milestone for Cytonics, and we couldn't have done it without you. For those who missed out on this round of funding, we will be raising capital again soon, providing another opportunity to join us as we advance CYT-108 through Phase 2 clinical studies. Join our mailing list by visiting www.cytonics.com. Stay tuned! Thank you for your continued support and belief in our mission. Together, we are making history by giving 600M suffering people their lives back! #Biotechnology #RegenerativeMedicine #CytonicsInnovations #Osteoarthritis #InvestInHealth #HealthTech